In this recent preclinical work entitled Metronomic cyclophosphamide activation of anti-tumor immunity: tumor model, mouse host, and drug schedule dependence of gene responses and their upstream regulators published in BMC Cancer, the team from David Waxman, Division of Cell and Molecular Biology, Department of Biology and Bioinformatics Program, Boston University report on the pro-immune effect of metronomic cyclophosphamide using different cell lines and schedule of cyclophosphamide to (...)